Fig. 3.

Sig1R agonists demonstrating anti-seizure effects and their corresponding high-affinity targets. (A) Heatmap demonstrates the binding affinities (K_i) to targets of compounds at concentrations below 10 µM (< 1 ×10^-5). Affinities of compounds were obtained from the PubChem and Binding Databases (accessed from May 25, 2022, to June 28, 2022). TMEM97 – transmembrane protein 97; EBP – emopamil binding protein; ERG2 – C-8 sterol isomerase; AchE – acetylcholine esterase; M1-M5 – muscarinic receptors; nAChRs – nicotinic acetylcholine receptors; VachT – vesicular acetylcholine transporter; NET – norepinephrine transporter; alpha-1 and alpha-2: adrenergic receptors; SERT – serotonin transporter; 5-HT1–7 – serotonin receptor subtypes; DAT – dopamine transporter; D1 and D2 – dopamine receptors; H1-H3 – histamine receptors; Mu, Kappa, Delta – opioid receptor subtypes; NMDAR – N-methyl-D-aspartate receptors; Na⁺, K⁺ and Ca²⁺ – corresponding ion channels. (B) Correlation of the binding of Sig1R agonists to Sig1R and to muscarinic M1 receptors. DTG – ditolylguanidine. Graphs were generated using GraphPad Prism software. For more details, see Table 1.